Plus Therapeutics Advances Capital Raise Amid SEC Filings

Introduction

PLUS THERAPEUTICS INC (NASDAQ: PSTV) is a clinical-stage pharmaceutical company headquartered in Houston, Texas, developing targeted radiotherapeutics for rare and difficult-to-treat cancers. On June 25, 2025, the stock closed at $0.4384, reflecting a 134.44 percent increase, with a trading volume of 131,050,096 shares.

Corporate Structure

Founded in 2019, Plus Therapeutics employs between 11 and 50 people. Its leadership team includes:

• Marc H. Hedrick, M.D., President & CEO, who oversees strategic vision and clinical development
• Andrew Sims, CFO, with over 25 years of financial and M&A experience in the life sciences sector
• Kyle Guse, CFO & General Counsel, responsible for legal and regulatory affairs

The company collaborates with principal investigators at academic centers and has established a supply chain through strategic partnerships for manufacturing and future commercialization.

Recent Developments and News

On May 23, 2025, Plus Therapeutics received a notification of deficiency from Nasdaq due to the delayed filing of its Form 10-Q for the quarter ended March 31, 2025. The company is required to submit a compliance plan by July 21, 2025, and anticipates resuming a normal filing schedule for the remainder of the year.

On June 23, 2025, three SEC filings were made effective:

• Notice of Effectiveness (Form S-1), which confirmed the effectiveness of its registration statement
• Registration Withdrawal Request (Form RW), which withdrew a previously filed Form S-3 while preserving paid fees for future use
• Prospectus (Rule 424(b)(3)), under which Lincoln Park Capital Fund, LLC may purchase up to 17 million shares of common stock, potentially raising gross proceeds of up to $50 million

Additionally, in June 2025, the FDA cleared the Investigational New Drug application for REYOBIQ™ for pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma and ependymoma. This trial, referred to as the ReSPECT-PBC trial, is funded by a $3 million grant from the U.S. Department of Defense.

The company also reorganized a previously announced $15 million equity financing on March 4, 2025, which aimed to reduce potential dilution of its shares.

Financial and Strategic Analysis

In the third quarter of 2023, Plus Therapeutics reported grant revenue of $1.059 million, an operating loss of $3.536 million, and a net loss of $17.401 million. Net loss per share increased to $1.19 from $0.75 year-over-year, largely due to increased financing expenses and changes in the fair value of derivative instruments.

The company’s strategic focus is on two lead programs:

• REYOBIQ™ (rhenium Re-186 obisbemeda), targeting central nervous system cancers, including recurrent glioblastoma and leptomeningeal metastases
• 188RNL-BAM, a next-generation radioembolization therapy for solid organ cancers, such as hepatocellular carcinoma and metastatic colorectal cancer

REYOBIQ™ has received orphan drug and Fast Track designations from the FDA. Plus Therapeutics acquired the CNSide® Platform for use in clinical studies and plans to initiate a multi-dose trial in the first half of 2025. A Phase 2 trial for recurrent glioblastoma is targeted for full enrollment by the end of 2025.

To support ongoing trials and operations, the company has arranged to raise up to $50 million through a securities sale to Lincoln Park Capital. This arrangement includes a $500,000 commitment fee and may be drawn upon in tranches as share purchases occur.

Market Position and Industry Context

Plus Therapeutics operates within the precision radiotherapeutics niche, combining Rhenium radioisotopes with nanoliposomes and biodegradable microspheres to deliver localized radiation doses. This platform is designed to enhance tumor targeting while minimizing damage to healthy tissue. Its focus on rare central nervous system cancers and liver tumors addresses significant unmet needs in oncology, setting it apart from broader radiotherapeutic approaches.

TL;DR

Plus Therapeutics received a Nasdaq deficiency notification regarding its delayed Q1 2025 Form 10-Q but expects to comply by July 21, 2025. On June 23, 2025, its S-1 became effective, its S-3 was withdrawn, and a prospectus with Lincoln Park Capital initiated a potential $50 million capital raise. The FDA cleared an IND for pediatric high-grade glioma and ependymoma, supported by a $3 million DoD grant, in addition to existing orphan drug and Fast Track designations for REYOBIQ™. The company is advancing clinical trials for CNS and liver cancer indications, with full enrollment in the ReSPECT-GBM Phase 2 study aimed by December 2025.